ReviewAmerican journal of hematology2021

Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials.

Jason R Westin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.